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Abstract  
 The varicella zoster virus is a member of the human herpes virus family. This virus 
infects humans in temperate regions around the world and produces a primary varicella infection, 
commonly known as “chickenpox” (Bricout, 2014). Subsequently, the virus becomes latent in 
the sensory ganglia waiting for an opportune time to reactivate as herpes zoster (shingles). There 
are over one million cases of herpes zoster cases in the United States annually (Weaver, 2007). 
Episodes of herpes zoster typically cause severe pain and distress and up to a third of these 
patients develop a chronic neuropathic pain syndrome known as postherpetic neuralgia (PHN). 
In 2006, the Food & Drug Administration (FDA) approved the Zostavax ®, a vaccine to prevent 
outbreaks of herpes zoster. This independent study aims to determine the incidence of 
postherpetic neuralgia in immunized individuals versus those who have not been vaccinated for 
prevention of herpes zoster.  
Keywords: postherpetic neuralgia, prevention, herpes zoster, zoster vaccine, and Zostavax. 
Background 
Herpes zoster, also known as shingles, is a viral infection caused by reactivation of a 
latent varicella zoster virus (VZV). This virus becomes latent in the sensory ganglia of the 
affected person and reappears as herpes zoster (Gabutti, Valente, Sulcaj, & Stefanati, 2014) in 
approximately 20-30% of the population (Jeon, 2015). This reoccurrence is thought to be related 
to the normal aging process in which there is a decrease in the overall immune response (Bricout 
et al., 2014). Specifically, there is less varicella zoster specific T-cell mediated immunity in the 
later years of life. This theory holds true for immune compromised patients, who are also at 
increased risk for developing the infection. However, 90% of individuals with herpes zoster have 
otherwise intact immune responses, which makes it very difficult for practitioners to predict 
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those at increased risk. Nevertheless, identified risk factors may include immune compromise, 
sex, family history of herpes zoster, ethnicity, physical or emotional trauma, stress, diabetes, 
depression, or genetic predisposition (Bricout et al., 2014, p. 2).  
The patient infected with herpes zoster typically presents with a painful erythematous 
skin lesion in the affected dermatome (Jeon, 2015). It is classically a vesicular lesion, occurring 
unilaterally on a single dermatome (Bricout et al., 2014). The location correlates to the sensory 
ganglion in which the latent varicella virus was reactivated. Greater than 50% of herpes zoster 
infections occur in the thoracic dermatomes. The cranial region is the next most common, and 
potentially more severe, as it may involve the “ophthalmic division of the trigeminal nerve” 
(Bricout et al., 2014).  
The pain related to herpes zoster occurs as the virus replicates within the basal ganglia, 
damaging the nerve (Kanbayashi & Hosokawa, 2013). There are three distinctive phases of pain 
response with this disease. The first is the prodromal period. This period occurs prior to the onset 
of rash and the patient may or may not experience pain. Next, the acute phase begins with a rash 
that generally lasts 2-4 weeks. The chronic pain phase is also considered to be the phase of 
postherpetic neuralgia (PHN). This is pain that occurs intermittently or continues for greater than 
three months after onset of the rash (Bricout et al., 2014). 
Postherpetic neuralgia often takes several forms including allodynia, hyperpathia, and 
dysesthesia (Kanbayashi & Hosokawa, 2013). Allodynia refers to the perception of nonpainful 
stimuli as painful. Hyperpathia describes the intensification of slightly painful stimulation that is 
perceived as agonizing. Dysesthesia presents through atypical sensations that lack the presence 
of stimuli. The pain associated with postherpetic neuralgia can be debilitating and greatly impact 
the individual’s quality of life. This is especially true in elderly adults where herpes zoster may 
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impair activities of daily living resulting in altered mood or depression. Even more burdensome 
is the fact that the neuropathic pain can be very difficult for healthcare providers to manage.  
Prevention of herpes zoster has improved through the development of the Zostavax ®, a 
live, attenuated varicella zoster virus vaccine. This vaccine specifically enhances the varicella 
zoster virus cell mediated immunity (Kanbayashi & Hosokawa, 2013). Obviously, prevention of 
herpes zoster alleviates risk of the patient developing postherpetic neuralgia. While the vaccine is 
currently approved in the United States for patients over fifty years old, it is not recommended 
until the age of sixty (Kanbayashi & Hosokawa, 2013). Only fifty year olds who have had an 
outbreak of herpes zoster or those with a chronic disease such as diabetes mellitus, chronic renal 
failure, or rheumatoid arthritis are recommended to receive the vaccination. The efficacy of the 
vaccine is also limited to only five years (Kanbayashi & Hosokawa, 2013).  
At this time there is no proven effective prophylaxis or recommendation for the 
prevention of postherpetic neuralgia (Kanbayashi & Hosokawa, 2013). This independent study 
aims to determine the efficacy of the varicella zoster vaccine in preventing the condition. The 
foundation of this report is based on the case of a 52 year old otherwise healthy male who 
presented with an acute phase herpes zoster infection. 
Case Report 
History 
 This independent study is based on the case of a fifty-two year old male patient who 
presented with left sided facial irritation, pruritus, erythema, and vesicular rash. He stated that his 
symptoms began with an intensely “itchy” feeling near his left eye one week ago. Three days 
prior to our encounter, he developed a “rash and blisters”. He states that his symptoms have 
become more intense since the onset. The patient describes himself to be generally healthy with 
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no other complaints at the time of visit. He relates that until recently he was unable to afford 
health insurance and therefore does not have a primary care provider. He is also not up to date 
with recommended screenings for his age. The patient did report having all recommended 
immunizations as a child, however denies any in his adult years. He denies any surgeries or 
severe conditions as a child, although he does recall being told he had chickenpox when he was 
very young. Currently, he is employed full-time as a seasonal tax preparer and regularly 
participates as a standardized patient model for the local nursing and medical schools. The 
patient is single, never married, and has no children. He denies any use of tobacco, illicit drug, or 
alcohol products, and has no known allergies. He does not take any scheduled medications or 
nutritional supplements, however does take acetaminophen as needed for mild pain relief. I 
conducted a thorough review of family history and the patient denied having any relatives with 
known cardiovascular disease, cancer, stroke, or diabetes mellitus.  
Review of Systems 
 A complete review of systems was completed at the time of his examination. The patient 
denied fever, chills, fatigue, or weight changes. As previously discussed, the patient did relate to 
having a pruritic, vesicular rash near his left eye. He denied any other skin rash, lesion, or 
bruising. The patient also denied headache, loss of consciousness, impaired vision, hearing loss, 
ear pain, altered sense of smell, postnasal drainage, sore throat, or hoarseness. He denied cough, 
shortness of breath, chest pain, palpitations, claudication, history of anemia, nausea, vomiting, or 
constipation. He has no known endocrine disorders, no genitourinary symptoms, no joint pain or 
stiffness, and denies any syncopal episodes, tremors, or seizures. The patient discussed that due 
to his employment and busy time of the year he was experiencing somewhat more stress than 
usual and admitted he was not getting adequate nightly rest. 
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Physical Exam 
 The patient’s vital signs were taken prior to physical examination and he was found to 
have a pulse of 88 beats per minute, blood pressure of 152/92 mmHg, respiratory rate of 16 
breaths per minute, temperature of 97.4 degrees Fahrenheit, and weight of 140 pounds. The 
patient is fifty-two years old, and a general appearance of a middle aged Caucasian male with an 
appropriate weight for height and no obvious nutritional deficits. There were no evident 
cognitive, speech or language defects. The patient did have a visibly erythematous patch 
measuring 5x3cm, with multiple confluent, herpetiform vesicles to the lateral aspect of his left 
orbit at the level of the maxillary (V2) dermatome. The patient had otherwise normal facial 
symmetry and characteristics, 20/20 visual acuity with Snellen eye chart, no peripheral field 
deficits, intact extraocular movements, and equal pupillary response to light and accommodation. 
The patient’s conjunctiva were clear and sclera were white. No abnormal findings were found on 
assessment of the patient’s ears, nose, or throat. The patient had no thyroid tenderness or 
nodules, normal anterior/posterior chest diameter, and his breath sounds were clear bilaterally to 
auscultation. The patient had a regular heart rate and rhythm with normal S1 and S2 heart tones. 
The patient’s abdomen was non-tender with no masses found to palpation. There were also no 
other skin lesions or rashes found throughout the course of the physical examination.  
Management of Care 
 The patient was found to have several pertinent findings classical for making the 
diagnosis of herpes zoster (shingles). The patient had a unilateral erythematous vesicular rash 
that did not cross the midline and remained with the maxillary (V2) dermatome. The patient did 
not have any complaints of pain, however described it to be quite pruritic.  
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The differential diagnosis of herpes zoster is usually made clinically and without 
laboratory testing. The classic vesicular lesions along a single dermatome confirm diagnosis 
(Whitley, 2015). During the prodromal period, however, the diagnosis can be quite difficult and 
is usually confirmed once the lesions have appeared.  
 The treatment regimen for herpes zoster include a regimen of antivirals and symptomatic 
treatment including adequate analgesia. Patients should be started on acyclovir, valacyclovir, or 
famciclovir for seven days as soon as diagnosis is made and within forty eight to seventy two 
hours of rash onset (Whitley, 2015). Patients with ocular manifestations should be treated with a 
ten day course of the oral antivirals. Valacyclovir and famcyclovir are the preferred treatments in 
terms of efficacy due to pharmacokinetics and dynamics, however may be cost prohibitive. It is 
also important that patients are provided with adequate analgesia for acute neuritis and 
postherpetic neuralgia which may include regimens of narcotics, nonnarcotics, or both (Whitley, 
2015). Additionally, some studies have shown that treatment with glucocorticoids accelerated 
return of quality of life and decreased the length of use of analgesics (Whitley, 2015). 
 The patient for this case study was educated on the overall cause, course, and 
manifestations of herpes zoster. He was also informed of the potential risk of zoster opthalmicus 
and that I would suggest referring him to an ophthalmologist for prevention of ocular 
impairment. Due to cost, the patient was started on acyclovir 800mg orally five times per day for 
ten days. For analgesia, the patient was given gabapentin 300mg orally three times per day along 
with tramadol 50mg every six hours. I discussed with the patient that his response to gabapentin 
and tramadol may cause drowsiness so he should not take these medications while at work. We 
also discussed the importance of keeping the vesicles covered and avoid exposure to 
unvaccinated and nonimmune individuals to prevent transmission of the virus.  
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 Other considerations for this patient include his general health maintenance. The patient 
does not currently have a primary care provider and is not up to date with his recommended 
health screenings. The patient has recently enrolled in a health insurance plan and the next step 
for this patient would be to establish care with a primary care provider. The patient is due for 
immunizations, as well as colon cancer, blood pressure, cholesterol, and diabetes screening 
(MedlinePlus, 2015). The patient was actually hypertensive at his visit and this was discussed 
with him. I stressed that it was very important that he establish care with a provider to ensure that 
all of these needs were addressed.  
Literature Review 
Search Strategies 
 For the process of reviewing literature in support of this topic, I electronically accessed 
the Harley E. French Library of the Health Sciences at the University of North Dakota, 
specifically utilizing two search engines, the Cumulative Index to Nursing and Allied Health 
Literature (CINAHL) and PubMed. My topic focused on prevention of postherpetic neuralgia by 
increasing specific cell mediated immunity via administration of a Varicella Zoster Vaccine. 
Again, the trade name for this vaccine is “ZostaVax”. Based on this information I was able to 
focus my search criteria to “postherpetic neuralgia”, “prevention”, “herpes zoster”, “zoster 
vaccine”, and “ZostaVax”.  
 With “English” and “results within the last ten years” filters applied, my search yielded a 
total of nine applicable articles that were accessible for online viewing. Two of which were 
retrieved from the CINAHL search and nine from the PubMed database.  
Findings 
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 There have been a number of trials focused on the use of a varicella zoster vaccine to 
reduce the incidence of herpes zoster. These include the Shingles Prevention Study (SPS), 
Zostavax ® Efficacy and Safety Trial (ZEST), Short Term Persistence Study (STPS), and Long 
Term Persistence Study (LTPS). These studies along with findings from several other cohort and 
longitudinal studies will be discussed to reinforce the outcome of reduced intensity and length of 
postherpetic neuralgia symptoms related to varicella zoster immunization. 
Shingles Prevention Study. The shingles prevention study (SPS) is a clinical study with 
a subject population of 38,546. The research was based around the fact that herpes zoster and 
postherpetic neuralgia are known to have many deleterious effects and substantial increases in 
morbidity of older adults (Oxman & Levin, 2008). In addition, the researchers understood that 
the incidence of both conditions increased as the age related cell mediated immunity to varicella 
zoster declined. Since varicella zoster vaccines increase this immunity, their hypothesis was that 
vaccination would provide protection to the study population from both herpes zoster and 
postherpetic neuralgia (Oxman & Levin, 2008). 
 The SPS was a multicenter, double-blinded, placebo controlled, randomized clinical trial 
made up of immunocompetent participants over the age of sixty years old (Gabutti et al., 2014). 
Study participants were followed for 182 days. The participants must have had a memory of 
varicella zoster or resided for at least thirty years in an endemic region of the virus. Patients who 
were excluded from the trial included those with no history of zoster, allergy to any components 
of the vaccine, or immunosuppression of any kind (Gabutti et al., 2014). The primary focus of 
this study was to determine safety and efficacy of the varicella vaccine with specific evaluation 
of decreased burden of illness.  Burden of illness was based on “incidence, severity and duration 
of acute and chronic pain related to herpes zoster during a follow-up period of at least six 
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months” (Gabutti et al., 2014, p. 132). The secondary focus of this trial was to evaluate the 
effectiveness of the vaccine to reduce incidence of postherpetic neuralgia. 
 The results of the Shingles Prevention Study were quite significant. The overall level of 
efficacy was 51.3% with a reduction of burden of illness of 61.1% (Gabutti et al., 2014). The 
overall effectiveness of the vaccine to prevent postherpetic neuralgia was 66.5% (Gabutti et al., 
2014). In ages 60-69 there was 65.7% efficacy with a 66.8% reduction in ages greater than 70 
years. Overall, there was a 73% reduction in the number of cases of herpes zoster with “severe 
and long-lasting pain” (Kanbayashi & Hosokawa, 2013, p.2) 
 Short Term Persistence Substudy. The Short Term Persistence Substudy (STPS) began 
as a method to assess and track the efficacy of the zoster vaccine. This study reenrolled 
participants from the Shingles Prevention Study. The population was made up of 7,320 vaccine 
and 6,950 placebo recipients (Schmader et al., 2012). The researchers kept the methods of 
surveillance, case determination, and follow-up exactly the same as the SPS trial. The “vaccine 
efficacy for herpes zoster burden of illness, incidence of postherpetic neuralgia, and incidence of 
herpes zoster were assessed for the STPS population, for the combined SPS and STPS 
population, and for each year through year 7 after vaccination” Schmader et al., 2012, p. 1320).  
 Results of the substudy were not as robust as the original Shingles Prevention Study. The 
vaccine’s efficacy on burden of illness dropped to 50.1% from 61.1% (Schmader et al., 2012). 
Postherpetic neuralgia efficacy decreased from an incidence of 66.5% to 60.1%. The overall 
efficacy of the vaccine decreased from 51.3% to 39.6%, however the researchers note that this 
difference was not statistically significant.  Final conclusions of the STPS revealed that there was 
a decrease in the vaccine efficacy after the first year of administration with subsequent declines 
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in the years after. The efficacy of the vaccine did, however, remain statistically significant for 5 
years post vaccination (Schmader et al., 2012).   
 Long Term Persistence Substudy. The Long Term Persistence Substudy (LTPS) was 
conducted similar to the STPS, however it monitored vaccine efficacy from 5 up to 11 years 
postvaccination (Morrison et al., 2015). The LTPS population was derived from participants of 
the Shingles Prevention Study. Unlike the Short Term Persistence Study, however, did not utilize 
placebo recipients and therefore unable to have an unvaccinated control group. The Long Term 
Persistence Substudy enrolled a total 6,867 SPS vaccine recipients.  
 The results of the study found that the estimated vaccine efficacy for herpes zoster burden 
of illness dropped to 37.3% from 61.1% (Morrison et al., 2012). Efficacy of postherpetic 
neuralgia declined to 35.4% from 66.5% and overall efficacy for prevention of herpes zoster 
declined from 51.3% to 21.1% (Morrison et al., 2012). All three of these measures decreased 
from years 7-11. Efficacy for reduction of burden of illness remained greater than zero through 
year ten after vaccination, however the vaccines efficacy of decreasing incidence of herpes zoster 
remained significantly greater than zero through year 8 of study (Morrison et al., 2012). Overall 
conclusions revealed that vaccine efficacy waned over time.   
 Zoster Efficacy and Safety Trial. The Zoster efficacy and Safety Trial (ZEST) was 
conducted in North America and Europe from October 2007-January 2010. This study was a 
double-blinded, placebo controlled, randomized clinical trial. Similar to the SPS, ZEST 
participants required a positive memory of varicella or lived at least 30 years in a region endemic 
to the virus (Gabutti et al., 2014). Subjects of this trial were 50-59 years of age and given a single 
dose zoster vaccine or placebo. A total of 22,439 pariticpants were enrolled in this study (Gabutti 
et al., 2014). 
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 The primary study endpoint of this trial was evaluating the overall incidence of herpes 
zoster post varicella vaccination (Keating, 2013). Total efficacy was found to be 69.8% (Gabutti 
et al., 2014). Total efficacy was staged into four time periods; 0-0.5 years, 0.5-1 years, 1.0-1.5 
years, and greater than 1.5 years. Overall, efficacy for these time periods were 76.9%, 64.0%, 
65.2%, and 75.3% (Keating, 2013).  Severity-by-duration pain scores were also lower in the 
vaccinated population versus the placebo group. The reduction in pain score for the vaccinated 
group was 73.0% (Keating, 2013). It is important to note however that there was a major 
difference between the collection time period of ZEST and SPS pain/burden of illness scores of 
21 days (ZEST) and 182 days (SPS) (Keating, 2013). 
 Additional Research. Several other studies have been conducted focusing on the 
efficacy of the varicella vaccine in the reduction of postherpetic neuralgia. Tseng et al. (2015, p. 
1222) conducted a cohort study of “1,155 individuals who were vaccinated against herpes zoster 
at age ≥60 years and had an herpes zoster episode after vaccination”. This cohort was matched at 
a 1:1 ratio with unvaccinated patients of same sex and age. Medical records were reviewed by 
trained medical residents to monitor pain at intervals up to six months after diagnosis of herpes 
zoster and compared with the pain levels of unvaccinated patients (Tseng et al., 2015). Their 
findings concluded that vaccination for herpes zoster is “associated with a lower risk of PHN in 
women but not in men” (Tseng et al., 2015). 
 Bricout et al. (2014, p.1) conducted a “longitudinal, prospective study in 108 general 
practices throughout Italy to assess how many immunocompetent patients aged ≥50 years with 
newly diagnosed herpes zoster develop herpes zoster associated pain, its duration and 
management over 6 months”. The researchers assessed pain via direct questioning and classified 
postherpetic neuralgia by symptoms of pain lasting greater than 3 months. The group also 
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assessed quality of life via questionnaire. At the time of this study, 2009-2010, implementation 
of a varicella vaccine was not implemented and no mention of immunization history was 
discussed. The researchers also discussed that many, yet not all, patients received recommended 
antiviral therapy. 
 Bricout et al. (2014) discovered that 89.6% of the group described pain related to herpes 
zoster. Of them, 20.6% had pain at 3 months and 9.2% of patients had pain at 6 months. They 
concluded that herpes zoster and postherpetic neuralgia do carry a burden on patients, especially 
elderly, and there is a need for prevention and intervention to reduce the burden of illness in this 
population. 
Discussion 
 Postherpetic neuralgia carries a serious burden of illness and decreases quality of life 
especially in the elderly population. The pain related to PHN may be responsible for “depression, 
fatigue, insomnia, altered activities of daily living, and decreased socialization” (Tseng et al. 
2015, p. 1222).  These patients may also have symptoms of anorexia, decreased physical activity, 
and experience altered mental status. These effects can be especially detrimental in the elderly 
population. Treatment options are often initiated at time of onset of rash and require accurate 
clinical diagnosis. Effectiveness of treatment options vary on an individual basis and elderly 
patients may not be candidates for many pharmacological regimens due to complex 
comorbidities. Prevention or symptom reduction is vital to ensuring quality of life and decreasing 
the burden of illness in this population.  
 There has been a significant amount of research conducted regarding the ability of the 
Zostavax vaccine to prevent or decrease morbidity related to post herpetic neuralgia. The 
foundation of the research focused on four clinical trials: SPS, LTPS, ZEST, and STPS. All of 
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the studies found that patients who receive the vaccination have significantly less risk of 
developing herpes zoster. In addition, the vaccine decreases burden of illness for a period of at 
least 5 years with benefits through 10 years post-vaccination. Therefore, this independent study 
found that the Zostavax decreases the incidence of postherpetic neuralgia by decreasing the 
incidence of herpes zoster as well as the duration and intensity of related symptoms. 
 
Learning Points 
 Zoster vaccine is proven to be statistically effective for prevention of herpes zoster and 
postherpetic neuralgia for 5 years. 
 Zoster vaccine decreases intensity and duration of postherpetic neuralgia. 
 New guidelines are needed to address the vaccine’s decreased efficacy after 5 years. 
 Postherpetic neuralgia may be more severe in males, however more research is needed to 
confirm this assumption.  
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